13th Annual Patient-Reported Outcome Consortium Workshop
Register Now for This Virtual Workshop!
On April 13-14, 2022, the 13th Annual Patient-Reported Outcome Consortium Workshop will be held in a virtual format. We encourage you to attend both days. To register for both days of the workshop, simply click the “Register Now” button and complete the brief form. You will receive a confirmation email message that includes an option to add the events to your calendar.
The agenda for the 2-day workshop, including session objectives, is below. The workshop begins each day at 11:00 AM Eastern Time (US).
| Agenda – April 13, 2022 | |
|---|---|
| 11:00 – 11:20 am ET (20 min) |
Welcome and Patient-Reported Outcome Consortium Update
Provide a high-level summary of the recent accomplishments and ongoing activities within the Patient-Reported Outcome Consortium |
| 11:20 – 12:30 pm ET (70 min) |
Session 1: FDA Update
Provide an update on FDA’s Clinical Outcome Assessment Qualification Program and other FDA initiatives |
| 12:30 – 12:50 pm ET (20 min) | Break – 20 min |
| 12:50 – 2:20 pm ET (90 min) |
Session 2: Advancing the Use and Interpretation of Meaningful Within-Person Change Thresholds
Examine three examples that advance the use of meaningful within-person change thresholds |
| 2:20 – 2:30 pm ET (10 min) | Day 1 Wrap Up |
| Agenda – April 14, 2022 | |
|---|---|
| 11:00 – 11:20 am ET (20 min) |
eCOA: Getting Better Together Initiative Update
Provide a brief update on the eCOA: Getting Better Together Initiative, an ongoing collaboration between the PRO Consortium and eCOA Consortium |
| 11:20 – 12:50 pm ET (90 min) |
Session 3: Using Digital Health Technology to Measure What Matters
Discuss how digital health technology can be used to measure what is important |
| 12:50 – 1:00 pm ET (10 min) | Workshop Wrap Up |
NOTE: Session presentations will be recorded and posted to the PRO Consortium’s web page following the workshop. Posters summarizing the status of the PRO Consortium’s working groups and highlighting the activity within the eCOA Consortium and the Rare Disease COA Consortium are available below:
